Format

Send to

Choose Destination
Wien Med Wochenschr. 2013 Feb;163(3-4):65-72. doi: 10.1007/s10354-012-0169-x. Epub 2012 Dec 20.

STW 5 (Iberogast®)--a safe and effective standard in the treatment of functional gastrointestinal disorders.

Author information

1
Life Sciences Consultancy, Brunnthal-Hofolding, Germany.

Abstract

Functional dyspepsia (FD) and irritable bowel syndrome (IBS) are frequent disorders affecting quality of life. They often require long-term treatment. Abdominal symptoms of both disorders can overlap, making differential diagnosis and treatment challenging. The extracts of the herbal combination preparation STW 5 (Iberogast(®)) exert pharmacological effects in different gastrointestinal regions and can address symptoms of both FD and IBS. This review summarizes safety and efficacy data of 12 clinical trials using STW 5 in FD and IBS since 1990. Double-blind and randomized studies versus placebo or active control found statistically significant effects of STW 5 on patients' symptoms with a comparable efficacy to a standard prokinetic. Non-interventional and retrospective studies confirmed these effects. Various studies evaluated the tolerability profile of STW 5: the incidence of adverse drug reactions was 0.04%. The worldwide spontaneous reporting system confirmed this profile. STW 5 has a favorable tolerability which is relevant for long-term treatment.

PMID:
23263639
PMCID:
PMC3580135
DOI:
10.1007/s10354-012-0169-x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center